DE60336266D1 - Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl-piperazinderivate und deren verwendung als neurokinin antagonisten - Google Patents

Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl-piperazinderivate und deren verwendung als neurokinin antagonisten

Info

Publication number: DE60336266D1
Authority: DE; Germany
Prior art keywords: pyrrolidin; piperidin; substituted; piperazine derivatives; neurokinin antagonists
Prior art date: 2002-12-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60336266T

Other languages

English (en)

Inventor

Frans Eduard Janssens

Francois Maria Sommen

Boeck Benoit De

Joseph E Leenaerts

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Pharmaceutica NV

Original Assignee

Janssen Pharmaceutica NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-23

Filing date

2003-12-17

Publication date

2011-04-14

2003-12-17 Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV

2011-04-14 Application granted granted Critical

2011-04-14 Publication of DE60336266D1 publication Critical patent/DE60336266D1/de

2023-12-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

DE60336266T 2002-12-23 2003-12-17 Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl-piperazinderivate und deren verwendung als neurokinin antagonisten Expired - Lifetime DE60336266D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP0214831		2002-12-23
PCT/EP2003/051041 WO2004056799A2 (en)	2002-12-23	2003-12-17	Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists

Publications (1)

Publication Number	Publication Date
DE60336266D1 true DE60336266D1 (de)	2011-04-14

Family

ID=32668698

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60336266T Expired - Lifetime DE60336266D1 (de)	2002-12-23	2003-12-17	Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl-piperazinderivate und deren verwendung als neurokinin antagonisten

Country Status (30)

Country	Link
US (1)	US7795261B2 (de)
EP (1)	EP1581518B1 (de)
JP (1)	JP4746878B2 (de)
KR (1)	KR101049073B1 (de)
CN (1)	CN100586945C (de)
AR (1)	AR042651A1 (de)
AT (1)	ATE500242T1 (de)
AU (1)	AU2003302488B2 (de)
BR (1)	BR0317658A (de)
CA (1)	CA2508657C (de)
CL (1)	CL2003002725A1 (de)
CY (1)	CY1112601T1 (de)
DE (1)	DE60336266D1 (de)
DK (1)	DK1581518T3 (de)
EA (1)	EA009078B1 (de)
ES (1)	ES2361161T3 (de)
HR (1)	HRP20050556B1 (de)
IL (1)	IL169336A (de)
JO (1)	JO2696B1 (de)
MX (1)	MXPA05006887A (de)
MY (1)	MY145135A (de)
NO (1)	NO331174B1 (de)
NZ (1)	NZ541035A (de)
PA (1)	PA8593301A1 (de)
PL (1)	PL376048A1 (de)
PT (1)	PT1581518E (de)
SI (1)	SI1581518T1 (de)
TW (1)	TWI329109B (de)
UA (1)	UA80584C2 (de)
WO (1)	WO2004056799A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2847160A1 (fr) *	2002-11-20	2004-05-21	Oreal	Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
AU2005234596B8 (en)	2004-04-13	2011-06-16	Incyte Holdings Corporation	Piperazinylpiperidine derivatives as chemokine receptor antagonists
WO2005123081A2 (en) *	2004-06-22	2005-12-29	Janssen Pharmaceutica N.V.	(2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia
US7880002B2 (en) *	2004-12-29	2011-02-01	Millennium Pharmaceuticals, Inc.	Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US7635698B2 (en) *	2004-12-29	2009-12-22	Millennium Pharmaceuticals, Inc.	Compounds useful as chemokine receptor antagonists
CN101137657B (zh) *	2005-03-08	2011-02-02	詹森药业有限公司	作为神经激肽（nk1）拮抗剂的二氮杂-螺-[4.4]-壬烷衍生物
DE102005038947A1 (de) *	2005-05-18	2006-11-30	Grünenthal GmbH	Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
EP2099454A4 (de) *	2006-11-17	2010-11-10	Abbott Lab	Aminopyrrolidine als chemokinrezeptor-antagonisten
MX2009010499A (es)	2007-03-31	2009-10-19	Intervet Int Bv	Procesos para elaborar zilpaterol y sales del mismo.
RU2442786C2 (ru) *	2007-03-31	2012-02-20	Интервет Интернэшнл Б.В.	Способы получения зилпатерола и его солей
CA2679991C (en) *	2007-03-31	2013-02-26	Intervet International B.V.	Processes for making zilpaterol and salts thereof
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en)	2007-06-04	2011-02-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2010529069A (ja) *	2007-06-07	2010-08-26	エフ．ホフマン−ラロシュアーゲー	Ｎｋ３アンタゴニストとしてのプロリンアミド誘導体
JP2011528375A (ja)	2008-07-16	2011-11-17	シナジーファーマシューティカルズインコーポレイテッド	胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US8507535B2 (en) *	2010-07-07	2013-08-13	Hoffmann-La Roche Inc.	Methyl-pyrrolidine ether derivatives
BR112015003376A8 (pt) *	2012-08-23	2018-01-23	Alios Biopharma Inc	composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
EP3574907B1 (de)	2015-05-18	2023-08-23	KaNDy Therapeutics Limited	Ein nk1/nk3-rezeptorantagonist zur behandlung von geschlechtshormonabhängigen erkrankungen
US10774091B2 (en)	2018-03-14	2020-09-15	KaNDy Therapeutics Limited	Soft gelatin capsule formulation
EP3886854A4 (de)	2018-11-30	2022-07-06	Nuvation Bio Inc.	Pyrrol- und pyrazolverbindungen und verfahren zu deren verwendung
US12533358B1 (en)	2025-05-14	2026-01-27	Bayer Consumer Care Ag	Methods of treatment with elinzanetant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY110227A (en)	1991-08-12	1998-03-31	Ciba Geigy Ag	1-acylpiperindine compounds.
US5589489A (en) *	1993-12-15	1996-12-31	Zeneca Limited	Cyclic amide derivatives for treating asthma
NZ321575A (en)	1995-10-30	1999-05-28	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW382017B (en)	1995-12-27	2000-02-11	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
AU7788500A (en)	1999-10-25	2001-05-08	Janssen Pharmaceutica N.V.	Use of substance p antagonists for influencing the circadian timing system
GB0025354D0 (en) *	2000-10-17	2000-11-29	Glaxo Group Ltd	Chemical compounds
US6642226B2 (en) *	2001-02-06	2003-11-04	Hoffman-La Roche Inc.	Substituted phenyl-piperidine methanone compounds
FR2820426B1 (fr) *	2001-02-07	2007-05-11	Condat Sa	Gel d'isolation thermique a reticulation controlee pour les lignes de transport d'hydrocarbures petroliers
MY141736A (en)	2002-10-08	2010-06-15	Elanco Animal Health Ireland	Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

2003
- 2003-12-15 JO JO2003174A patent/JO2696B1/en active
- 2003-12-17 UA UAA200505412A patent/UA80584C2/uk unknown
- 2003-12-17 MX MXPA05006887A patent/MXPA05006887A/es active IP Right Grant
- 2003-12-17 EA EA200501041A patent/EA009078B1/ru not_active IP Right Cessation
- 2003-12-17 KR KR1020057009197A patent/KR101049073B1/ko not_active Expired - Fee Related
- 2003-12-17 ES ES03810849T patent/ES2361161T3/es not_active Expired - Lifetime
- 2003-12-17 AT AT03810849T patent/ATE500242T1/de active
- 2003-12-17 AU AU2003302488A patent/AU2003302488B2/en not_active Ceased
- 2003-12-17 SI SI200331992T patent/SI1581518T1/sl unknown
- 2003-12-17 EP EP03810849A patent/EP1581518B1/de not_active Expired - Lifetime
- 2003-12-17 DK DK03810849.4T patent/DK1581518T3/da active
- 2003-12-17 CA CA2508657A patent/CA2508657C/en not_active Expired - Fee Related
- 2003-12-17 PL PL03376048A patent/PL376048A1/xx not_active Application Discontinuation
- 2003-12-17 BR BR0317658-4A patent/BR0317658A/pt not_active IP Right Cessation
- 2003-12-17 PT PT03810849T patent/PT1581518E/pt unknown
- 2003-12-17 WO PCT/EP2003/051041 patent/WO2004056799A2/en not_active Ceased
- 2003-12-17 DE DE60336266T patent/DE60336266D1/de not_active Expired - Lifetime
- 2003-12-17 JP JP2004561504A patent/JP4746878B2/ja not_active Expired - Fee Related
- 2003-12-17 CN CN200380106356A patent/CN100586945C/zh not_active Expired - Fee Related
- 2003-12-17 US US10/540,447 patent/US7795261B2/en not_active Expired - Fee Related
- 2003-12-17 HR HRP20050556AA patent/HRP20050556B1/hr not_active IP Right Cessation
- 2003-12-17 NZ NZ541035A patent/NZ541035A/en not_active IP Right Cessation
- 2003-12-19 MY MYPI20034909A patent/MY145135A/en unknown
- 2003-12-19 PA PA20038593301A patent/PA8593301A1/es unknown
- 2003-12-22 TW TW092136343A patent/TWI329109B/zh not_active IP Right Cessation
- 2003-12-22 CL CL200302725A patent/CL2003002725A1/es unknown
- 2003-12-22 AR ARP030104776A patent/AR042651A1/es unknown
2005
- 2005-06-22 IL IL169336A patent/IL169336A/en not_active IP Right Cessation
- 2005-07-21 NO NO20053569A patent/NO331174B1/no not_active IP Right Cessation
2011
- 2011-06-01 CY CY20111100532T patent/CY1112601T1/el unknown

Also Published As

Publication number	Publication date
ES2361161T3 (es)	2011-06-14
ATE500242T1 (de)	2011-03-15
EA200501041A1 (ru)	2005-12-29
EP1581518B1 (de)	2011-03-02
IL169336A (en)	2013-01-31
PL376048A1 (en)	2005-12-12
TWI329109B (en)	2010-08-21
AU2003302488B2 (en)	2009-10-08
WO2004056799A3 (en)	2004-08-12
AR042651A1 (es)	2005-06-29
DK1581518T3 (da)	2011-06-06
TW200500359A (en)	2005-01-01
KR101049073B1 (ko)	2011-07-15
JP4746878B2 (ja)	2011-08-10
CA2508657C (en)	2013-02-19
SI1581518T1 (sl)	2011-06-30
BR0317658A (pt)	2005-12-06
CY1112601T1 (el)	2016-02-10
EP1581518A2 (de)	2005-10-05
JO2696B1 (en)	2013-03-03
NO20053569D0 (no)	2005-07-21
US7795261B2 (en)	2010-09-14
CL2003002725A1 (es)	2005-04-08
HK1087703A1 (zh)	2006-10-20
CN1726207A (zh)	2006-01-25
KR20050085098A (ko)	2005-08-29
EA009078B1 (ru)	2007-10-26
HRP20050556B1 (hr)	2014-03-28
NO20053569L (no)	2005-09-15
IL169336A0 (en)	2007-07-04
HRP20050556A2 (en)	2006-07-31
NZ541035A (en)	2008-05-30
AU2003302488A1 (en)	2004-07-14
CA2508657A1 (en)	2004-07-08
WO2004056799A2 (en)	2004-07-08
US20060040950A1 (en)	2006-02-23
UA80584C2 (uk)	2007-10-10
MY145135A (en)	2011-12-30
NO331174B1 (no)	2011-10-24
CN100586945C (zh)	2010-02-03
PT1581518E (pt)	2011-05-12
PA8593301A1 (es)	2004-08-31
MXPA05006887A (es)	2005-08-16
JP2006514027A (ja)	2006-04-27

Publication	Publication Date	Title
ATE500242T1 (de)	2011-03-15	Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl- piperazinderivate und deren verwendung als neurokinin antagonisten
DE60325493D1 (de)	2009-02-05	Substituierte 1,4-dipiperidin-4-yl-piperazinderivate und deren verwendung als neurokininantagonisten
ATE395339T1 (de)	2008-05-15	Biphenylderivate und deren verwendung als fungizide
ATE446953T1 (de)	2009-11-15	P2x7-rezeptorantagonisten und deren verwendung
DE60113719D1 (de)	2006-02-09	Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
DE60332023D1 (de)	2010-05-20	Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
ATE378338T1 (de)	2007-11-15	Pyrrolopyridinderivate und deren verwendung als crth2-antagonisten
DE60325761D1 (de)	2009-02-26	Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
DE60133897D1 (de)	2008-06-19	Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
DE60324767D1 (de)	2009-01-02	Fluoro substituierte cycloalkanindole und deren verwendung als prostaglandin d2 rezeptor antagonisten
ATE346056T1 (de)	2006-12-15	Substituierte phenylacetamide und deren verwendung als glucokinaseaktivatoren
DE60308998D1 (de)	2006-11-23	N-aryl-2-oxazolidinon-5-carbonsäureamide und deren derivate und deren verwendung als antibakterielle mittel
DE602005004144D1 (de)	2008-02-14	Octahydropyrroloä3,4-cüpyrrolderivate und deren verwendung als antivirale mitteln
DE602005023639D1 (de)	2010-10-28	Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten
DE60104776D1 (de)	2004-09-16	Diphenylharnstoffderivate und deren Verwendung als alpha2/5-HT2c Antagonisten
DE602005011593D1 (de)	2009-01-22	Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten
DE60114413D1 (de)	2005-12-01	Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
DE60321958D1 (de)	2008-08-14	Indazolderivate und ihre verwendung als crf antagonisten
ATE471938T1 (de)	2010-07-15	Substituierte diazaspiroä4.5üdecanderivate und deren verwendung als neurokininantagonisten
ATE551329T1 (de)	2012-04-15	Chinazolinonderivate und deren verwendung als cb- agonisten
DE602005007002D1 (de)	2008-07-03	Substituierte 4-alkyl- und 4-alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten
ATE353083T1 (de)	2007-02-15	Naphthyridin-derivate und ihre verwendung als fungizide
ATE361295T1 (de)	2007-05-15	Substituierte diketopiperazine und deren verwendung als oxytocynantagonisten
ATE401333T1 (de)	2008-08-15	1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors
DE60311277D1 (de)	2007-03-08	Benzotriazabicyclische derivate und deren verwendung als beta-lactamaseinhibitoren und antibakterielle mittel